StockWatch
·
ASTRAZENECA PHARMA INDIA · NPPA · DELHI HIGH COURT · BSE 506820

Delhi High Court bars coercive steps on NPPA's ₹151.2 Cr Symbicort demand — paused, not decided

The order halts recovery of ≈₹151.20 Cr — alleged Symbicort Turbuhaler overcharge plus interest to Oct 30 — roughly 0.96% of market cap and ≈89% of trailing four-quarter profit. Next hearing: January 11, 2027.

ASTRAZENAstraZeneca Pharma India Ltd02 Nov 2026 · 4 min read
Size tier

MID-CAP by market cap ≈ ₹15,761.3 Cr

Demand paused

≈₹151.20 Cr

alleged overcharge + interest to Oct 30, 2026

Vs trailing profit

≈89%

of four-quarter net profit, ₹169.62 Cr

Next hearing

Jan 11, 2027

Delhi High Court

Last close

₹6,304.5 Nov 2 · -0.1% on the filing session

From 52-week high

−36.0% adjusted high ₹9,849.50 (Nov 3, 2025)

What happened

An interim order lands in a ten-year pricing dispute

-0.1% (Nov 2, filed mid-session at 11:51 IST)
legal

Company discloses Delhi High Court order: no coercive steps by NPPA until the January 11, 2027 hearing

AstraZeneca Pharma India informed the exchange that the Delhi High Court, by an order dated October 29, 2026 (received October 30), has directed that no coercive steps be taken by the NPPA in its matter over alleged overcharging on Symbicort Turbuhaler 160/4.5 (Inhaler) under the Drugs (Prices Control) Order, 2013, until the next hearing on January 11, 2027. The amount NPPA cannot coercively recover until then is approximately ₹151,19,66,035 — i.e. ≈₹151.20 crore — comprising the alleged overcharged amount and interest up to October 30, 2026.

Read:The demand equals roughly 0.96% of market cap but ≈89% of the trailing four quarters' net profit — material if it ever crystallises, immaterial to the balance sheet while it is only paused. The filing resolves nothing on merits; it buys time to the January hearing.

BSE filing, Nov 2, 2026, 11:51 IST

The filing lays out the sequence plainly. Further to a show cause notice dated September 11, 2025, the company received a notice from the National Pharmaceutical Pricing Authority on July 29, 2026 — followed by a reminder — alleging overcharging on Symbicort Turbuhaler 160/4.5 (Inhaler) for the period May 2016 to November 2025 under DPCO, 2013. The company disclosed that notice to exchanges on July 30, 2026, and challenged the demand before the Delhi High Court. The court's October 29 order directs that no coercive steps be taken by NPPA until the next date of hearing.

The operative direction, as the company's filing records it
Order directing NPPA that no coercive steps be taken by NPPA in this matter, until the next date of hearing i.e. January 11, 2027

— AstraZeneca Pharma India, Regulation 30(7) disclosure to BSE, November 2, 2026 (Annexure A)

What the order is not matters as much as what it is. The filing states only that coercive recovery is barred until January 11, 2027 — it does not say the demand was set aside, reduced, or decided on merits. This suggests the ₹151.20 crore remains a live claim whose outcome depends on the High Court proceedings; the interest component, computed up to October 30, 2026, would by its nature keep accruing on NPPA's arithmetic if the demand survives, though the filing does not state the ongoing accrual rate. Nor does the filing state whether any provision has been made in the accounts — the quarterly results due this week are the next scheduled place that could become visible.

The scale

₹151 crore against a ₹15,800 crore company

≈₹151.20 Cr

demand paused — alleged overcharge + interest to Oct 30, 2026

≈0.96%

of market cap (₹15,761.3 Cr at ₹6,304.5)

≈89%

of trailing four-quarter net profit (₹169.62 Cr)

9½ years

alleged overcharge period, May 2016 – Nov 2025

Both framings are honest, and they point in different directions. Against a market cap of ≈₹15,761.3 crore (2.50 crore shares at the ₹6,304.5 close), the demand is under 1% — a number the stock can absorb. Against earnings power it is far larger: the last four reported quarters (Q2 FY26 through Q1 FY27) produced ₹169.62 crore of net profit in aggregate, so a one-time outflow of ₹151.20 crore would be equivalent to roughly 89% of a year's profit at the current run rate. That asymmetry — small for the equity value, large for a single year's P&L — is why the mechanics and the hearing date matter more than the headline.

  1. NPPA show cause notice on Symbicort Turbuhaler 160/4.5 pricing (referenced in the Nov 2 filing)

  2. NPPA notice received, alleging overcharging under DPCO 2013 for May 2016 – Nov 2025; a reminder followed

  3. Company discloses the NPPA notice to exchanges

  4. Delhi High Court order: no coercive steps by NPPA until the next hearing

  5. Company receives the order; demand quantified at ≈₹151.20 Cr including interest to this date

  6. Disclosure filed with BSE at 11:51 IST, during market hours

  7. Next date of hearing before the Delhi High Court

The market's same-session verdict was close to indifference: the filing hit the exchange at 11:51 IST on November 2 and the stock closed at ₹6,304.5, down about 0.1% from the October 30 close of ₹6,312.50. One reading, offered as inference, is that an interim no-coercive-steps direction was the expected path once the company had taken the demand to court in a dispute already public since July.

The tape

A stock rebuilding from its 52-week low

₹, adjusted daily close
5,422.926,189.096,955.257,721.428,487.586,304.508-0608-2709-1810-1211-02Delhi HC order disclosed · -0.1%
AstraZeneca Pharma India (BSE 506820), split/bonus-adjusted daily closes, Aug 6 – Nov 2, 2026. Source: BSE adjusted price series.

The dispute has played out against a weak tape. Over the sixty sessions in view the stock slid from ₹8,075.50 on August 6 to a closing low of ₹5,719.50 on October 8; the pack's separately reported 52-week adjusted low of ₹5,640 on October 9 is an intraday figure, not a closing price. It has since recovered about 10.2% from that closing low to ₹6,304.5 — yet remains 36.0% below the 52-week adjusted high of ₹9,849.50 set on November 3, 2025. The court order arrived into a stock already repriced well below last year's peak, which may partly explain the muted reaction.

The earnings backdrop

Revenue compounding, margin compressing — and results on November 5

Quarterly standalone · ₹ Cr
QuarterRevenuePBTNet ProfitOPMEPS (₹)
Q1 FY27682.7950.7537.937.13%15.17
Q4 FY26578.6158.1444.8810.34%17.95
Q3 FY26611.5746.5432.597.57%13.04
Q2 FY26559.0972.8254.2212.5%21.69
Q1 FY26526.3174.755.8315.34%22.33

Standalone, as filed. Q1 FY27 revenue grew 29.7% over Q1 FY26; net profit fell 32.1% over the same comparison.

The earnings table frames why a ₹151 crore claim is not trivial here. Q1 FY27 revenue of ₹682.79 crore was up 29.7% year on year, but net profit of ₹37.93 crore was down 32.1%, with operating margin at 7.13% against 15.34% a year earlier — the company is growing the top line faster than it is converting it to profit. The next data point is near: the board meets on November 5, 2026 to consider the unaudited results for the quarter and half year ended September 30, with the trading window closed for designated persons from September 16 to November 7, both days inclusive.

What to watch

The dates and documents that change this picture

  • Jan 11, 2027 hearing

    Whether the Delhi High Court extends the no-coercive-steps direction, modifies it, or moves toward deciding the challenge to the ₹151.20 Cr demand.

  • Nov 5 results

    The Q2/H1 FY27 statements — whether they carry any disclosure or provision relating to the NPPA matter, and whether the margin compression visible in Q1 persists.

  • Further Reg 30 filings

    Any fresh order, notice or company update on the NPPA matter between now and the hearing — the July notice, the reminder and this order all arrived as Regulation 30 disclosures.

The November 2 disclosure changes the timetable, not the substance, of AstraZeneca Pharma India's pricing dispute. A demand of approximately ₹151.20 crore — alleged overcharge on Symbicort Turbuhaler 160/4.5 plus interest to October 30, 2026 — cannot be coercively recovered by NPPA until the Delhi High Court's next hearing on January 11, 2027. The claim itself, covering May 2016 to November 2025, remains before the court.

For holders, the arithmetic is the anchor: roughly 0.96% of market cap, roughly 89% of trailing four-quarter net profit. The data suggests the market treated the interim order as expected — a roughly 0.1% decline close-to-close on the filing session — leaving the January hearing and Thursday's results (November 5) as the two scheduled events that could move the number from paused to resolved, in either direction.

Informational and educational content only. Not investment advice.